Molly O’Shea@MollySOShea1d ago

BREAKING: Only 10% of AI companies are worth their valuations. The other 90% aren't. Annie Lamont, Co-Founder & Managing Partner of @OakHCFT #1 healthcare investor on the Midas List, 40+ years investing, 70+ exits, 15 IPOs, & $7B+ firm that just closed $2B Fund VI FULL INTERVIEW We sat down at the @NYSE to talk AI drug discovery, China's rise in pharma research, Devoted Health as the leading example of AI in healthcare, & frontier labs as the next healthcare acquirers. We cover: › Pharma now sends 50% of its outside research spending to China, a shift from the last 4 years › @chaidiscovery's AI makes antibody design labs 100x more productive › @DevotedHealth tripled in size in the last year › Oak committed $100M on day 1 to Auger, ex-Amazon exec Dave Clark's AI supply chain startup › Oak’s latest investment in Halluminate, a data research lab building reinforcement-learning environments for financial services 𝐓𝐈𝐌𝐄𝐒𝐓𝐀𝐌𝐏𝐒 (00:00) Annie Lamont, Co-Founder & MP at Oak HC/FT (00:56) How AI reshaped Healthcare & Fintech (05:35) Why AI in biotech is finally exploding (08:35) The China threat to American drug development (17:03) Are Hospitals actually at risk from AI? (23:26) How AI will transform your healthcare experience (26:32) How the AI shift changed the way Oak evaluates companies (32:58) How M&A is changing in Healthcare (35:43) What a great acquisition looks like (50:26) Halluminate (53:20) Augur (58:49) What's kept Annie Lamont going for four decades